News
CSBR
9.47
+0.74%
0.07
We Ran A Stock Scan For Earnings Growth And Champions Oncology (NASDAQ:CSBR) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Simply Wall St. · 07/23 13:57
Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Champions Oncology press release (NASDAQ:<...
Seekingalpha · 07/21 20:41
Champions Oncology Q4 EPS $(0.02) Misses $0.02 Estimate, Sales $12.90M Beat $12.72M Estimate
Champions Oncology (NASDAQ:CSBR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 50 percent increase over losses of $(0.04) per share from the
Benzinga · 07/21 20:02
Champions Oncology Reports Quarterly Revenue of $12.9 Million
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for the year and fourth fiscal ...
ACCESSWIRE · 07/21 20:00
-- Earnings Flash (CSBR) CHAMPIONS ONCOLOGY Posts Q4 Loss $-0.02
MT Newswires · 07/21 16:11
Earnings Scheduled For July 21, 2022
  Companies Reporting Before The Bell • SAP (NYSE:SAP) is projected to report quarterly earnings at $1.15 per share on revenue of $7.56 billion.
Benzinga · 07/21 08:41
A Preview Of Champions Oncology's Earnings
Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Thursday, 2022-07-21. Here's what investors need to know before the announcement. Analysts estimate that Champions Oncology will report an earnings per share (EPS) of $...
Benzinga · 07/20 18:05
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022
HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and ...
ACCESSWIRE · 07/14 20:00
Investors in Champions Oncology (NASDAQ:CSBR) have made a impressive return of 197% over the past five years
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
Simply Wall St. · 06/13 10:30
Champions Oncology Announces A Partnership With Cyclica To Develop Small Molecule Therapeutics; Terms Not Disclosed
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc.
Benzinga · 05/31 12:34
Champions Oncology to Collaborate With Cyclica to Jointly Develop Small Molecule Therapeutics
MT Newswires · 05/31 11:15
Champions Oncology, Inc.'s (NASDAQ:CSBR) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Champions Oncology (NASDAQ:CSBR) has had a rough month with its share price down 7.0%. However, stock prices are...
Simply Wall St. · 05/02 17:16
Here's How Much You Would Have Made Owning Champions Oncology Stock In The Last 5 Years
Champions Oncology (NASDAQ:CSBR) has outperformed the market over the past 5 years by 7.88% on an annualized basis.
Benzinga · 03/21 16:01
Champions Oncology Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q3, Champions Oncology (NASDAQ:CSBR) earned $787.00 thousand, a 184.12% increase from the preceding quarter. Champions Oncology also posted a total of $13.19 million in sales, a 11.94% increase since Q2.
Benzinga · 03/16 15:04
Champions Oncology Non-GAAP EPS of $0.07, revenue of $13.2M
Champions Oncology press release (NASDAQ:CSBR): Q3 Non-GAAP EPS of $0.07. Revenue of $13.2M.
Seekingalpha · 03/15 21:02
Champions Oncology Fiscal Q3 EPS Declines, Revenue Increases
MT Newswires · 03/15 17:05
-- Earnings Flash (CSBR) CHAMPIONS ONCOLOGY Posts Q3 EPS $0.07, vs. Street Est of $0.04
MT Newswires · 03/15 17:03
Earnings Preview For Champions Oncology
Champions Oncology (NASDAQ:CSBR) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Champions Oncology will report an earnings per share (EPS) of $0...
Benzinga · 03/14 14:04
Do Institutions Own Champions Oncology, Inc. (NASDAQ:CSBR) Shares?
Every investor in Champions Oncology, Inc. ( NASDAQ:CSBR ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 03/07 18:10
Champions Oncology, GigaMune collaborate on next-gen T cell therapies
Champions Oncology (CSBR +2.2%) is collaborating with GigaMune for next generation T cell therapies and cancer diagnostics. The partnership will combine Champions' novel autologous Tumor Infiltrating Lymphocyte (TIL) platform with
Seekingalpha · 02/15 15:33
More
Webull provides a variety of real-time CSBR stock news. You can receive the latest news about Champions Oncolo through multiple platforms. This information may help you make smarter investment decisions.
About CSBR
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverages the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.